undamentalytics Newsletter

Jazz Pharmaceuticals plc revenue

Jazz Pharmaceuticals plc's revenue was $4.27bn in fiscal 2025, up 4.9% on the year before. Since fiscal 2009 ($128m) it has grown at a compound 24.5% a year. Over the last twelve months it was $4.72bn.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Jazz Pharmaceuticals plc: revenue history, annual
Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue1281742725868721,1731,3251,4881,6191,8912,1622,3643,0943,6593,8344,0694,2684,718
Growth on the year before—+35.3%+56.7%+115.2%+48.9%+34.4%+13.0%+12.3%+8.8%+16.8%+14.3%+9.3%+30.9%+18.3%+4.8%+6.1%+4.9%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Product and Services Product Sales Net of Deductions $4B 95.3% ▲ 5.3%
Total Neuroscience (part of Product and Services Product Sales Net of Deductions) $2.9B 71.6% ▲ 6.7%
Total Oncology (part of Product and Services Product Sales Net of Deductions) $1.1B 28.1% ▲ 1.6%
Defitelio Defibrotide $199M 4.7% ▼ 7.9%
Geography
Region Revenue Share YoY
United States $3.8B 89.8% ▲ 4.7%
Europe $341M 8.0% ▲ 9.1%
Other Countries $94.9M 2.2% ▼ 1.3%

From Jazz Pharmaceuticals plc's 10-K filed February 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Jazz Pharmaceuticals plc $4.72bn 13.5% 7.5%
Elanco Animal Health Inc $5.02bn 12.0% 5.1%
Organon & Co. $6.10bn -3.2% -0.3%
Amneal Pharmaceuticals, Inc. $3.12bn 9.3% 10.5%
Royalty Pharma plc $2.54bn 10.0% 2.4%
Zoetis $9.52bn 1.5% 5.0%

Compare with peers

Head to head: ELAN vs JAZZJAZZ vs OGNAMRX vs JAZZ

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Jazz Pharmaceuticals plc's SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Jazz Pharmaceuticals plc.